Shares of uniQure plummeted nearly 45% pre-market after the FDA deemed Phase I/II data insufficient for AMT-130's marketing application. The regulator stated the data, compared to an external control, doesn't serve as primary evidence of effectiveness. Despite the setback, uniQure's CEO remains confident in the data and plans continued dialogue with the FDA.